Literature DB >> 24135786

Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma.

Tianjiao Lyu1, Nan Jia1, Jieyu Wang1, Xiaohui Yan1, Yinhua Yu2, Zhen Lu3, Robert C Bast3, Keqin Hua1, Weiwei Feng1.   

Abstract

The initiation of angiogenesis can mark the transition from tumor dormancy to active growth and recurrence. Mechanisms that regulate recurrence in human cancers are poorly understood, in part because of the absence of relevant models. The induction of ARHI (DIRAS3) induces dormancy and autophagy in human ovarian cancer xenografts but produces autophagic cell death in culture. The addition of VEGF to cultures maintains the viability of dormant autophagic cancer cells, thereby permitting active growth when ARHI is downregulated, which mimics the "recurrence" of growth in xenografts. Two inducible ovarian cancer cell lines, SKOv3-ARHI and Hey-ARHI, were used. The expression level of angiogenesis factors was evaluated by real-time PCR, immunohistochemistry, immunocytochemistry and western blot; their epigenetic regulation was measured by bisulfite sequencing and chromatin immunoprecipitation. Six of the 15 angiogenesis factors were upregulated in dormant cancer cells (tissue inhibitor of metalloproteinases-3, TIMP3; thrombospondin-1, TSP1; angiopoietin-1; angiopoietin-2; angiopoietin-4; E-cadherin, CDH1). We found that TIMP3 and CDH1 expression was regulated epigenetically and was related inversely to the DNA methylation of their promoters in cell cultures and in xenografts. Increased H3K9 acetylation was associated with higher TIMP3 expression in dormant SKOv3-ARHI cells, while decreased H3K27me3 resulted in the upregulation of TIMP3 in dormant Hey-ARHI cells. Elevated CDH1 expression during dormancy was associated with an increase in both H3K4me3 and H3K9Ac in two cell lines. CpG demethylating agents and/or histone deacetylase inhibitors inhibited the re-growth of dormant cancer cells, which was associated with the re-expression of anti-angiogenic genes. The expression of the anti-angiogenic genes TIMP3 and CDH1 is elevated during dormancy and is reduced during the transition to active growth by changes in DNA methylation and histone modification.

Entities:  

Keywords:  angiogenesis; dormancy; histone modification; methylation; ovarian cancer; recurrence

Mesh:

Substances:

Year:  2013        PMID: 24135786      PMCID: PMC3933493          DOI: 10.4161/epi.26675

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  40 in total

1.  Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer.

Authors:  Zhen Lu; Robert Z Luo; Hongqi Peng; Daniel G Rosen; E Neely Atkinson; Carla Warneke; Maosheng Huang; Arata Nishmoto; Jinsong Liu; Warren S-L Liao; Yinhua Yu; Robert C Bast
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

2.  Epigenetic cancer therapy makes headway.

Authors:  George S Mack
Journal:  J Natl Cancer Inst       Date:  2006-10-18       Impact factor: 13.506

3.  Vorinostat approved for rare lymphoma.

Authors:  Cheryl A Thompson
Journal:  Am J Health Syst Pharm       Date:  2006-11-15       Impact factor: 2.637

Review 4.  E-cadherin and hereditary diffuse gastric cancer.

Authors:  Corrado Pedrazzani; Giovanni Corso; Daniele Marrelli; Franco Roviello
Journal:  Surgery       Date:  2007-11       Impact factor: 3.982

5.  ARHI/NOEY2 inactivation may be important in breast tumor pathogenesis.

Authors:  Hisashi Hisatomi; Kumi Nagao; Kazuyuki Wakita; Norio Kohno
Journal:  Oncology       Date:  2002       Impact factor: 2.935

6.  Angiostatic activity of DNA methyltransferase inhibitors.

Authors:  Debby M E I Hellebrekers; Kam-Wing Jair; Emmanuelle Viré; Sayaka Eguchi; Nicole T H Hoebers; Mario F Fraga; Manel Esteller; François Fuks; Stephen B Baylin; Manon van Engeland; Arjan W Griffioen
Journal:  Mol Cancer Ther       Date:  2006-02       Impact factor: 6.261

7.  Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors.

Authors:  Irene Dalai; Edoardo Missiaglia; Stefano Barbi; Giovanni Butturini; Claudio Doglioni; Massimo Falconi; Aldo Scarpa
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

Review 8.  Models, mechanisms and clinical evidence for cancer dormancy.

Authors:  Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

9.  NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas.

Authors:  Y Yu; F Xu; H Peng; X Fang; S Zhao; Y Li; B Cuevas; W L Kuo; J W Gray; M Siciliano; G B Mills; R C Bast
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

10.  E-cadherin expression in early gastric carcinoma and correlation with lymph node metastasis.

Authors:  Dong Yi Kim; Jae Kyoon Joo; Young Kyu Park; Seong Yeob Ryu; Hyun Soo Kim; Bok Kyun Noh; Kyung Hwa Lee; Jae Hyuk Lee
Journal:  J Surg Oncol       Date:  2007-10-01       Impact factor: 3.454

View more
  17 in total

1.  Angiopoietin-4 increases permeability of blood vessels and promotes lymphatic dilation.

Authors:  Cristina T Kesler; Ethel R Pereira; Cheryl H Cui; Gregory M Nelson; David J Masuck; James W Baish; Timothy P Padera
Journal:  FASEB J       Date:  2015-05-14       Impact factor: 5.191

Review 2.  The biology and clinical implications of prostate cancer dormancy and metastasis.

Authors:  Colm Morrissey; Robert L Vessella; Paul H Lange; Hung-Ming Lam
Journal:  J Mol Med (Berl)       Date:  2015-10-21       Impact factor: 4.599

3.  Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes.

Authors:  Anna Julia Wiecek; Daniel Hadar Jacobson; Wojciech Lason; Maria Secrier
Journal:  Front Cell Dev Biol       Date:  2021-07-09

Review 4.  Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications.

Authors:  Federico Rossari; Cristina Zucchinetti; Gabriele Buda; Enrico Orciuolo
Journal:  Cell Oncol (Dordr)       Date:  2019-08-07       Impact factor: 6.730

Review 5.  TIMPs: versatile extracellular regulators in cancer.

Authors:  Hartland W Jackson; Virginie Defamie; Paul Waterhouse; Rama Khokha
Journal:  Nat Rev Cancer       Date:  2016-12-09       Impact factor: 60.716

6.  The expression and significance of histone lysine methylation in endometrial cancer.

Authors:  Qing Li; Nan Jia; Xiang Tao; Keqin Hua; Weiwei Feng
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

7.  Regucalcin promotes dormancy of prostate cancer.

Authors:  Sambad Sharma; Xinhong Pei; Fei Xing; Shih-Ying Wu; Kerui Wu; Abhishek Tyagi; Dan Zhao; Ravindra Deshpande; Marco Gabriel Ruiz; Ravi Singh; Feng Lyu; Kounosuke Watabe
Journal:  Oncogene       Date:  2020-12-15       Impact factor: 9.867

Review 8.  Imprinting genes associated with endometriosis.

Authors:  Hiroshi Kobayashi
Journal:  EXCLI J       Date:  2014-03-13       Impact factor: 4.068

Review 9.  Original insights on thrombospondin-1-related antireceptor strategies in cancer.

Authors:  Albin Jeanne; Christophe Schneider; Laurent Martiny; Stéphane Dedieu
Journal:  Front Pharmacol       Date:  2015-10-29       Impact factor: 5.810

10.  Activation of anaphase-promoting complex by p53 induces a state of dormancy in cancer cells against chemotherapeutic stress.

Authors:  Yafei Dai; Lujuan Wang; Jingqun Tang; Pengfei Cao; Zhaohui Luo; Jun Sun; Abraha Kiflu; Buqing Sai; Meili Zhang; Fan Wang; Guiyuan Li; Juanjuan Xiang
Journal:  Oncotarget       Date:  2016-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.